<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00151125</url>
  </required_header>
  <id_info>
    <org_study_id>0403006</org_study_id>
    <secondary_id>0403006</secondary_id>
    <nct_id>NCT00151125</nct_id>
  </id_info>
  <brief_title>Phase II Study of IL-11 (Neumega) in Von Willebrand Disease</brief_title>
  <official_title>Phase II Comparison Study of Hemostatic Efficacy of Escalating Doses of Interleukin-11 (rhIL-11, Neumega) in Subjects With Type 1 Von Willebrand Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is testing the use of rhIL-11 (recombinant interleukin 11, Neumega) in individuals
      with Von Willebrand disease. The purpose is to evaluate:

        1. if rhIL-11 corrects VWF (Von Willebrand Factor) levels to normal

        2. if rhIL-11 and DDAVP together will boost VWF levels even higher

        3. the onset, peak, and duration of rhIL-11 effect

        4. if rhIL-11 is safe in individuals with Von Willebrand Disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single center, open-label, escalating dose Phase II comparison study
      of interleukin-11 (rhIL-11, Neumega) in subjects with type 1 Von Willebrand Disease (VWD).

      The purpose is to establish the clinical safety and hemostatic efficacy of rhIL-11 in
      individuals with type 1 Von Willebrand disease.

      Study subjects will include the following subjects:

        1. age &gt;= 18 years of age

        2. diagnosis of VWD confirmed by: 2a) at least 2 of 4 abnormal vWD-related coagulation
           tests; 2b) a past bleeding history

      A total of 10-16 subjects are anticipated to be enrolled and complete the study. The specific
      aims of the study are:

        1. to compare the hemostatic efficacy of three escalating doses of rhIL-11

        2. to determine the biologic effects of rhIL-11

        3. to determine whether DDAVP, when given after the seventh daily dose of rhIL-11, enhances
           hemostatic efficacy or rhIL-11

        4. to compare the safety of three escalating doses of rhIL-11

      Efficacy will be based on the number and percent increase of VWD-related coagulation tests
      into the normal range, or at least to 2-3 times baseline.

      Safety will be based on the number and frequency of adverse reactions, including fever,
      headache, fatigue, arthralgias, myalgias, fluid retention, and edema.

      The study will last up to 4 weeks per subject, and for 24 months for the entire study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number and percent increase of VWD coagulation tests after seven daily doses of rhIL-11, boosted by DDAVP day 7.</measure>
    <time_frame>The time frame is up to 14 days per subject.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number and frequency of IL-11 associated adverse events.</measure>
    <time_frame>The time frame is up to 14 days per subject.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mechanism of IL-11 biologic effect by VWFmRNA.</measure>
    <time_frame>The time frame is within 14 days per subject.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Von Willebrand Disease</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rhIL-11 (Interleukin-11, Neumega) 25 mcg/kg subcutaneously daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rhIL-11 (interleukin-11, Neumega) 50 mcg/kg subcutaneously daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rhIL-11 (Interleukin-11, Neumega) 10 mg/kg subcutaneously daily for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant interleukin-11</intervention_name>
    <description>25 mcg/kg subcutaneously daily for seven days</description>
    <arm_group_label>A</arm_group_label>
    <other_name>rhIL-11, Neumega</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant interleukin-11</intervention_name>
    <description>50 mcg/kg subcutaneously daily for 7 days</description>
    <arm_group_label>B</arm_group_label>
    <other_name>rhIL-11, Neumega</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant interleukin-11</intervention_name>
    <description>10 mcg/kg subcutaneously daily for 7 days</description>
    <arm_group_label>C</arm_group_label>
    <other_name>rhIL-11, Neumega</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females 18 years of age or older

          -  Confirmed VWD by 2 of 4 VWD coagulation tests abnormal

          -  A past bleeding history

          -  No hormone, oral contraceptive, estrogen use in past 8 weeks

          -  Willingness to have blood drawn

          -  Willingness to sign informed consent

        Exclusion Criteria:

          -  Presence of other bleeding disorder, e.g. acquired VWD, thrombocytopenia

          -  Use of estrogens, hormones, oral contraceptives in past 8 weeks

          -  Use of immunomodulatory or experimental drugs or diuretics

          -  Pregnant or lactating women

          -  Past cardiac disease, congestive failure, arrhythmia (e.g. atrial fibrillation, atrial
             flutter), hypertension, MI, stroke, or thrombosis

          -  Past allergic reaction to Neumega or DDAVP

          -  Surgery within the past 8 weeks

          -  Inability to comply with study protocol requirements

          -  Concomitant use of antiplatelet drugs, anticoagulants, dextran, aspirin, or NSAIDs

          -  Treatment with DDAVP, cryoprecipitate, whole blood, plasma, and plasma derivatives
             containing FVIII, VWF within 5 days of study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret V. Ragni, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hemophilia Center of Western Pennsylvania and General Clinical Research Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-4306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.clinicalresearch.pitt.edu</url>
    <description>Bleeding Disorders, Von Willebrand Disease</description>
  </link>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>May 16, 2016</last_update_submitted>
  <last_update_submitted_qc>May 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Margaret Ragni</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Von Willebrand Disease</keyword>
  <keyword>Bleeding</keyword>
  <keyword>Coagulation</keyword>
  <keyword>Hemostatic agent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Von Willebrand Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatics</mesh_term>
    <mesh_term>Oprelvekin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

